UnitedHealth stock price forecast: criminal probes pressure outlook as UNH declines 1.13%

Traders Union
All News
Financial News
UnitedHealth slides 1.13% to $336.80

Highlights

A U.S. Senate Judiciary Committee report alleges UnitedHealth used aggressive risk-adjustment coding in Medicare Advantage plans to boost government reimbursements above competitors.
The report cites over 50,000 internal documents and accuses UnitedHealth of incentivizing doctors and deploying AI to maximize risk scores for higher federal payments.
UnitedHealth is subject to ongoing Department of Justice civil and criminal investigations related to Medicare Advantage billing, though the company denies the Senate report’s characterizations.

Profit-driven risk coding scrutiny intensifies amid regulatory investigations

UnitedHealth is under renewed regulatory scrutiny after a U.S. Senate Judiciary Committee report alleged that the company employed aggressive risk-adjustment coding in its Medicare Advantage plans to boost government reimbursements. The report, referencing over 50,000 internal documents, accused UnitedHealth of incentivizing physicians to add diagnoses and using AI tools to maximize risk scores for profit, leading to higher federal payments than competitors. UnitedHealth is also facing ongoing civil and criminal investigations by the Department of Justice related to its Medicare Advantage billing. The company has rejected the Senate report’s characterizations and asserted compliance with regulatory standards.

Mixed momentum signals as trend weakness collides with buyer dominance

Momentum indicators show a mixed backdrop: the daily MACD points to mild bullish momentum, while the ADX (12.30) signals trend weakness and indecisiveness. The RSI (54.64) leans positive but is not overbought, and Stochastic RSI and CCI remain neutral, indicating no strong overbought or oversold condition. The Bull/Bear Power on the daily chart signals persistent buyer dominance but is classified as overbought, while intraday readings show sellers increasingly active. The Awesome Oscillator trend is neutral and does not reinforce a clear direction. Ichimoku’s Kijun level at $336.11 offers dynamic support, with the MA-200 at $343.46 as the next major resistance.

Rangebound outlook prevails as breakout risks remain limited

The expected trading range for UNH over the next five sessions is $336–$341, representing a typical volatility band relative to current levels. There is a very low probability (less than 20%) of a sustained upside move; weakness remains more likely in the short term. Price is likely to remain rangebound between support at $336 and resistance at $341, unless a breakout occurs. A move below $336 may trigger further declines toward the lower $330s, while a sustained advance above $341 would be required for a bullish reversal.

Viktoras Karapetjanc, expert at Traders Union, sees UnitedHealth as maintaining resilience despite facing regulatory headwinds. He believes the stock’s technicals and sentiment show constructive bias, with strong support and only moderate resistance ahead. The renewed regulatory attention adds near-term uncertainty, but longer-term fundamentals remain robust. Price action is likely to hold in its current range unless broader market or legal developments trigger a breakout. "If support near $336 is respected, I see potential for upside attempts, but caution is warranted until regulatory clarity improves."

Previously it was reported that UnitedHealth Group is exhibiting short- and medium-term momentum, trading above its 20- and 50-day averages but remaining below longer-term resistance at the 200-day average, with technical signals showing a mix of mild buying strength and emerging overbought risks. The price is expected to remain range-bound as bullish momentum stalls, with dynamic support near $336 and resistance around $344, while ongoing federal investigations add to market uncertainty.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.